https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43455 p < 0.001); whilst those with an unhealthy diet and no MVM or fish oil consumption were associated with a higher risk of obesity (p < 0.05). Compared to participants with a long-term healthy diet and no calcium consumption, the combination of a long-term healthy diet and calcium consumption was linked to a lower risk of CVD (IRR = 0.87, 95% CI: 0.78; 0.96). In conclusion, a long-term healthy diet combined with MVM or fish oil was associated with a lower incidence of CVD. Participants who maintained a healthy diet and used calcium supplements were associated with a lower incidence of obesity. However, these associations were not found among those with an unhealthy diet, despite taking similar supplements.]]> Wed 28 Sep 2022 14:35:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52440 Wed 11 Oct 2023 14:55:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31124 Wed 11 Apr 2018 16:45:05 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14924 Wed 11 Apr 2018 10:46:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12674 Wed 11 Apr 2018 09:57:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30805 Wed 11 Apr 2018 09:19:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47267 Wed 06 Mar 2024 15:38:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41409 Wed 03 Aug 2022 11:24:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45541 2) to investigate effects of fish oil (2000 mg docosahexaenoic acid + 400 mg eicosapentaenoic acid/day), curcumin (160 mg/day) or a combination of both on cerebrovascular function (measured by Transcranial Doppler ultrasound), systemic vascular function (blood pressure, heart rate and arterial compliance) and cardiometabolic (fasting glucose and blood lipids) and inflammatory (C-reactive protein) biomarkers. The primary outcome, cerebrovascular responsiveness to hypercapnia, was not affected by the interventions. However, cerebral artery stiffness was significantly reduced in males following fish oil supplementation (P = 0.007). Furthermore, fish oil reduced heart rate (P = 0.038) and serum triglycerides (P = 0.006) and increased HDL cholesterol (P = 0.002). Curcumin did not significantly affect these outcomes either alone or in combination with fish oil. Conclusion: Regular supplementation with fish oil but not curcumin improved biomarkers of cardiovascular and cerebrovascular function. The combined supplementation did not result in additional benefits. Further studies are warranted to identify an efficacious curcumin dose and to characterize (in terms of sex, BMI, cardiovascular and metabolic risk factors) populations whose cerebrovascular and cognitive functions might benefit from either intervention. Clinical trial registration: ACTRN12616000732482p.]]> Tue 14 Nov 2023 14:41:26 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41204 Thu 28 Jul 2022 11:26:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:660 Thu 25 Jul 2013 09:10:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51878 Thu 21 Sep 2023 10:23:40 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54277 Thu 15 Feb 2024 14:39:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18879 2; WC: 105 ± 16 and 110 ± 13 cm; BF: 48 ± 5 and 35% ± 6% in women and men respectively. Erythrocyte levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were similar in men and women while docosapentaenoic acid (DPA) was higher and EPA + DHA (Omega-3 Index) slightly lower in men than in women. Both DHA and EPA + DHA correlated inversely with BMI, WC and BF in women while DPA correlated inversely with BF in men. Quartile distributions and curvilinear regression of the Omega-3 Index versus BMI revealed a steep rise of BMI in the lower range of the Omega-3 Index in women, but no association in men. Thus the results highlight important gender differences in relationships of specific LC n-3 PUFA in erythrocytes to markers of adiposity. If these reflect causal relationships between LC n-3 PUFA consumption and risk of obesity, gender specific targeted interventions should be considered.]]> Sat 24 Mar 2018 10:29:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9455 Sat 24 Mar 2018 08:41:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20488 Sat 24 Mar 2018 07:59:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19402 Sat 24 Mar 2018 07:52:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19351 1 min was not significantly different between the groups (P = .9). There was a rebound increase in AT/AF burden in p3 in cross over patients (2.2% to 5.8%, P = .01) reaching a level similar to controls (crossover vs. controls, 5.8% vs. 4.3%, P = .63) and higher than those who continued fish oil for 12 months (crossover vs. continued intake 5.8% vs. 1.2%, P = .02). Fish oil patients had shorter duration episodes of AT/AF with no difference in frequency compared to controls. Conclusion: Long-term fish oil supplementation did not suppress AT/AF burden but may have attenuated its temporal progression related to aging and sinus node disease.]]> Sat 24 Mar 2018 07:52:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54738 Mon 11 Mar 2024 14:19:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:38520 Mon 09 May 2022 16:19:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36438 Mon 04 May 2020 12:30:03 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34250 75% cure rate following chemotherapy; there is an increasing population of survivors who live with chronic bone defects. Studies suggest that these defects are the result of reduced bone from increased marrow fat formation and increased bone resorption following chemotherapy. These changes probably result from altered expression/activation of regulatory molecules or pathways regulating skeletal cell formation and activity. Treatment with methotrexate, an antimetabolite commonly used in childhood oncology, has been shown to increase levels of proinflammatory/pro-osteoclastogenic cytokines (e.g., enhanced NF-κB activation), leading to increased osteoclast formation and bone resorption, as well as to attenuate Wnt signaling, leading to both decreased bone and increased marrow fat formation. In recent years, understanding the mechanisms of action and potential health benefits of selected nutraceuticals, including resveratrol, genistein, icariin, and inflammatory fatty acids, has led to preclinical studies that, in some cases, indicate efficacy in reducing chemotherapy-induced bone defects. We summarize the supporting evidence.]]> Fri 22 Feb 2019 16:56:01 AEDT ]]>